Introduction {#sec0005}
============

The atypical pneumonia case, caused by a novel coronavirus (2019-nCoV), was first reported and confirmed in Wuhan, China on December 31, 2019 ([@bib0090]). As of January 26 (17:00 GMT), 2020, there have been 2033 confirmed cases of 2019-nCoV infections in mainland China, including 56 deaths ([@bib0060]). The 2019-nCoV cases were also reported in Thailand, Japan, Republic of Korea, Hong Kong, Taiwan and the US, and all of these cases were exported from Wuhan; see the World Health Organization (WHO) news release <https://www.who.int/csr/don/en/> from January 14--21. The outbreak is still ongoing. A recently published preprint by Imai et al. estimated that a total of 1723 (95% CI: 427-4471) cases of 2019-nCoV infections in Wuhan had onset of symptoms by January 12, 2020 ([@bib0040]). The likelihood of travel related risks of disease spreading is suggested by [@bib0015]), which indicates the potentials of regional and global spread ([@bib0045]).

To the best of our knowledge, there is no existing peer-reviewed literature quantifying the transmissibility of 2019-nCoV as of January 22, 2020. In this study, we estimated the transmissibility of 2019-nCoV via the basic reproduction number, *R* ~0~, based on the limited data in the early phase of the outbreak.

Methods {#sec0010}
=======

We obtained the number of 2019-nCoV cases time series data in mainland China released by Wuhan Municipal Health Commission, China and National Health Commission of China from January 10 to January 24, 2020 from ([@bib0105]). All cases were laboratory confirmed following the case definition by the National Health Commission of China ([@bib0060]). Although the date of submission of this study is January 26, we choose to use data up to January 24. Note that the data of the most recent few days contain a number of infections that were infected outside Wuhan due to travel, and thus this part of the infections is excluded from the analysis.

Although there were cases confirmed on or before January 16, the official diagnostic protocol was released by WHO on January 17 ([@bib0095]). To adjust the impact of this event, we considered a time-varying reporting rate that follows a linear increasing trend, motivated by the previous study ([@bib0100]). We assumed that the reporting rate, *r*(*t*), started increasing on January 17, and stopped at the maximal level on January 21. The reporting rate increase corresponds to accounts for the announcement on improving the 2019-nCoV surveillance of the Hubei provincial government ([@bib0035]). The length of the reporting increasing part roughly equals the average of the incubation periods of two other well-known coronavirus diseases, i.e., the Middle East Respiratory Syndrome (MERS) and the Severe Acute Respiratory Syndrome (SARS), i.e., 5 days ([@bib0010], [@bib0050], [@bib0030]). Denoting the daily reported number of new cases by *c*(*t*) for the *t*-th day, then the adjusted cumulative number of cases, *C*(*t*), is $C\left( t \right) = \sum_{\tau = 0}^{t}c\left( \tau \right)/r\left( \tau \right)$. Instead of finding the exact value of *r*(*t*), we calculated the fold change in *r*(*t*) that is defined by the ratio of *r* on January 10 over that on January 24 minus 1. We illustrated six scenarios with 0- (no change), 0.5-, 1-, 2-, 4- and 8-fold increase in reporting rate, see [Figure 1](#fig0005){ref-type="fig"} (a), (c), (e), (g), (i) and (k).Figure 1The scenarios of the change in the reporting rate (top panels) and the exponential growth fitting (bottom panels). The top panels, i.e., (a), (c), (e), (g), (i) and (k), show the assumed change in the reporting rate. The bottom panels, i.e., (b), (d), (f), (h), (j) and (l), show the reported (or observed, green circles), adjusted (blue dots) and fitted (blue curve) number of 2019-nCoV infections, and the blue dashed lines are the 95%CI. The vertical grey line represents the date of January 16, 2020, after which the official diagnostic protocol was released by the WHO (World Health Organization, 2020). Panels (a) and (b) show the scenarios that the reporting rate was unchanged. Panels (c) and (d) show the scenarios that the reporting rate increased by 0.5-fold. Panels (e) and (f) show the scenarios that the reporting rate increased by 1-fold. Panels (g) and (h) show the scenarios that the reporting rate increased by 2-fold. Panels (i) and (j) show the scenarios that the reporting rate increased by 4-fold. Panels (k) and (l) show the scenarios that the reporting rate increased by 8-fold.Figure 1

Following previous studies ([@bib0110], [@bib0025]), we modelled the epidemic curve obeying the exponential growth. The nonlinear least square (NLS) framework is adopted for data fitting and parameter estimation. The intrinsic growth rate (*γ*) of the exponential growth was estimated, and the basic reproduction number could be obtained by *R* ~0~ = 1/*M*(−*γ*) with 100% susceptibility for 2019-nCoV at this early stage. The function *M*(∙) is the Laplace transform, i.e., the moment generating function, of the probability distribution for the serial interval (SI) of the disease ([@bib0110], [@bib0080]), denoted by *h*(*k*) and *k* is the mean SI. Since the transmission chain of 2019-nCoV remains unclear, we adopted the SI information from SARS and MERS, which share a similar pathogen as 2019-nCoV. We modelled *h*(*k*) as Gamma distributions with a mean of 7.6 days and standard deviation (SD) of 3.4 days for MERS ([@bib0005]), and mean of 8.4 days and SD of 3.8 days for SARS ([@bib0055]) as well as their average, see the row heads in [Table 1](#tbl0005){ref-type="table"} for each scenario.Table 1The summary table of the estimated basic reproduction number, *R*~0~, under different scenarios. The estimated *R*~0~ is shown as in the 'median (95%CI)' format. The 'reporting rate increased' indicates the number of fold increase in the reporting rate from January 17, when WHO released the official diagnostic protocol ([@bib0095]), to January 20, 2020.Table 1Reporting rate increasedEstimated *R*~0~Same as MERS SI 7.6 ± 3.4SI in average 8.0 ± 3.6Same as SARS SI 8.4 ± 3.8(unchanged)5.31 (3.99--6.96)5.71 (4.24--7.54)6.11 (4.51--8.16)0.5-fold4.52 (3.49--5.76)4.82 (3.69--6.20)5.14 (3.90--6.67)1-fold4.01 (3.17--5.02)4.26 (3.34--5.38)4.53 (3.51--5.76)2-fold3.38 (2.75--4.12)3.58 (2.89--4.39)3.77 (3.02--4.67)4-fold2.73 (2.31--3.22)2.86 (2.40--3.39)3.00 (2.50--3.58)8-fold2.16 (1.90--2.45)2.24 (1.96--2.55)2.32 (2.02--2.66)[^1]

Results and discussion {#sec0015}
======================

The exponential growth fitting results are shown in [Figure 1](#fig0005){ref-type="fig"}(b), (d), (f), (h), (j) and (l). The coefficient of determination, R-squared, ranges from 0.91 to 0.92 for all reporting rate changing scenarios, which implies that the early outbreak data were largely following the exponential growth. In [Table 1](#tbl0005){ref-type="table"}, we estimated that the *R* ~0~ ranges from 2.24 (95%CI: 1.96-2.55) to 5.71 (95%CI: 4.24-7.54) associated with an 8-fold to 0-fold increase in the reporting rate. All *R* ~0~ estimates are significantly larger than 1, which indicates the potential of 2019-nCoV to cause outbreaks. Since the official diagnostic protocol was released by WHO on January 17 ([@bib0095]), an increase in the diagnosis and reporting of 2019-nCoV infections probably occurred. Thereafter, the daily number of newly reported cases started increasing around January 17, see [Figure 1](#fig0005){ref-type="fig"}, which implies that more infections were likely being diagnosed and recorded. We suggested that changes in reporting might exist, and thus it should be considered in the estimation, i.e., 8-, 4- and 2-fold changes are more likely than no change in the reporting efforts. Although six scenarios about the reporting rate were explored in this study, the real situation is difficult to determine given limited data and (almost) equivalent model fitting performance in terms of R-squared. However, with increasing reporting rate, we found the mean *R* ~0~ is likely to be between 2 and 3.

Our analysis and estimation of *R* ~0~ rely on the accuracy of the SI of 2019-nCoV, which remains unknown as of January 25. In this work, we employed the SIs of SARS and MERS as approximations to that of 2019-nCoV. The determination of SI requires knowledge of the chain of disease transmission that needs a sufficient number of patient samples and periods of time for follow-up ([@bib0020]), and thus this is unlikely to be achieved shortly. However, using SIs of SARS and MERS as approximation could provide an insight to the transmission potential of 2019-nCoV at the early stage of the outbreak. We reported that the mean *R* ~0~ of 2019-nCoV is likely to be from 2.24 (8-fold) to 3.58 (2-fold), and it is largely in the range of those of SARS, i.e., 2-5 ([@bib0010], [@bib0055], [@bib0085]), and MERS, i.e., 2.7-3.9 ([@bib0050]).

We note that WHO reported the basic reproduction number for the human-to-human (direct) transmission ranged from 1.4 to 2.5 ([@bib0095]), which is marginally lower than ours. However, many of the existing online preprints estimate the mean *R* ~0~ ranging from 2 to 5 ([@bib0040], [@bib0070], [@bib0065], [@bib0075]), which is largely consistent with our results.

Conclusion {#sec0020}
==========

We estimated the mean *R* ~0~ of 2019-nCoV ranging from 2.24 (95%CI: 1.96-2.55) to 3.58 (95%CI: 2.89-4.39) if the reporting effort has been increased by a factor of between 8- and 2-fold, respectively, after the diagnostic protocol released on January 17, 2020 and many medical supplies reached Wuhan.
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[^1]: *Note*: 'SI' is serial interval. 'MERS' is Middle East Respiratory Syndrome, and 'SARS' is the Severe Acute Respiratory Syndrome.
